| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | SIR2; SIR2L1; SIR2alpha |
| Entrez GeneID | 93759 |
| WB Predicted band size | Calculated MW: 80 kDa; Observed MW: 120 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Recombinant protein of mouse SIRT1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于SIRT1抗体的3篇参考文献示例，包含文献名称、作者及摘要核心内容：
---
1. **文献名称**：*SIRT1 Promotes DNA Repair Activity and Deacetylation of Ku70*
**作者**：Cohen HY, et al.
**摘要**：该研究利用特异性SIRT1抗体，通过免疫沉淀和Western blot技术，揭示了SIRT1在DNA损伤修复中通过去乙酰化Ku70蛋白发挥保护作用，抗体的特异性在敲除细胞模型中得到验证。
---
2. **文献名称**：*Tissue-Specific Regulation of SIRT1 by Caloric Restriction*
**作者**：Sun L, et al.
**摘要**：研究采用多种SIRT1抗体检测不同组织中的蛋白表达，发现热量限制显著上调肝脏和脂肪组织中的SIRT1水平，抗体特异性通过组织敲除实验确认。
---
3. **文献名称**：*SIRT1 Improves Insulin Sensitivity in Adipose Tissue*
**作者**：Bordone L, et al.
**摘要**：通过SIRT1抗体进行免疫组化和Western blot分析，发现脂肪组织中SIRT1过表达可增强胰岛素敏感性，抗体在代谢疾病模型中的有效性得到验证。
---
这些文献均涉及SIRT1抗体的实验应用，包括特异性验证(如敲除模型或组织特异性检测)及在DNA修复、代谢调控等研究中的关键作用。建议通过PubMed或Google Scholar进一步检索具体DOI和期刊信息。
SIRT1 (silent mating type information regulation 2 homolog 1) is a NAD⁺-dependent class III histone deacetylase belonging to the sirtuin family. It plays critical roles in regulating cellular processes such as aging, metabolism, stress response, inflammation, and genome stability by deacetylating histone (e.g., H3K9. H4K16) and non-histone targets (e.g., p53. FOXOs, PGC-1α). SIRT1’s involvement in lifespan extension and age-related diseases has made it a key focus in biomedical research.
SIRT1 antibodies are essential tools for detecting and quantifying SIRT1 protein expression, localization, and activity in various experimental settings, including Western blotting, immunohistochemistry, immunoprecipitation, and immunofluorescence. These antibodies typically target specific epitopes within SIRT1’s conserved catalytic core domain (~250 amino acids) or variable N-/C-terminal regions. High-quality SIRT1 antibodies exhibit specificity validated by knockout controls or siRNA knockdown, as cross-reactivity with other sirtuins (e.g., SIRT2 or SIRT3) is a common challenge.
Research applications span cancer (tumor suppression vs. oncogenic roles), neurodegenerative disorders (e.g., Alzheimer’s), metabolic diseases (e.g., diabetes), and longevity studies. Commercial SIRT1 antibodies are available from multiple hosts (rabbit, mouse) and formats (monoclonal, polyclonal), with validation data critical for experimental reliability. Variability in post-translational modifications (e.g., phosphorylation) or tissue-specific isoforms may influence antibody performance, necessitating careful optimization for specific models.
×
